- Boceprevir
Drugbox
IUPAC_name = (1"R",2"S",5"S")-"N"- [(2Ξ)-4-amino-1-cyclobutyl-3,4-dioxobutan-2-yl)] - 3-{(2"S")-2- [(tert-butylcarbamoyl)amino] -3,3-dimethylbutanoyl}- 6,6-dimethyl-3-azabicyclo [3.1.0] hexane-2-carboxamide
width = 300
CAS_number = 394730-60-0
ATC_prefix =
ATC_suffix =
PubChem =
DrugBank =
chemical_formula =
C=27 | H=45 | N=5 | O=5
molecular_weight =
bioavailability =
protein_bound =
metabolism =
elimination_half-life =
excretion =
pregnancy_AU =
pregnancy_US =
pregnancy_category=
legal_AU =
legal_CA =
legal_UK =
legal_US =
legal_status =
routes_of_administration =Boceprevir (INN) is a protease inhibitor being studied as a treatment for
hepatitis C .cite journal |author=Degertekin B, Lok AS |title=Update on viral hepatitis: 2007 |journal=Curr. Opin. Gastroenterol. |volume=24 |issue=3 |pages=306–11 |year=2008 |month=May |pmid=18408458 |doi=10.1097/MOG.0b013e3282f70285 |url=http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?an=00001574-200805000-00007] cite journal |author=Njoroge FG, Chen KX, Shih NY, Piwinski JJ |title=Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection |journal=Acc. Chem. Res. |volume=41 |issue=1 |pages=50–9 |year=2008 |month=January |pmid=18193821 |doi=10.1021/ar700109k |url=http://dx.doi.org/10.1021/ar700109k]It is being developed by
Schering-Plough .cite press release|url=http://www.forbes.com/prnewswire/feeds/prnewswire/2008/04/26/prnewswire200804261200PR_NEWS_USPR_____NYSA004.html |title=Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL - Forbes.com |format= |publisher=Forbes.com |accessdate=2008-05-19]As of 2008 , it is in phase II clinical trials.References
Wikimedia Foundation. 2010.
